Kornimate/medical-research-clean huggingface dataset:
predictors of response to iron and erythropoietin stimulating agents

Conditions: Renal Failure Chronic; Anemia

Summary: the purpose of the study is to identify predictors of treatment response. this involves collected baseline clinical parameters and bloods for biochemical parameters prior to administering the study treatment. a positive outcome following treatment was defined as an uptitration of haemoglobin by greater than 5g/l within 2 months. the study evaluated the participants response to treatment against the clinical and biochemical information collected prior to treatment being received.


Eligibility criteria:
inclusion criteria: * all prevalent haemodialysis patients, established for greater than 3 months exclusion criteria: inability to consent bone marrow disorder transfusion dependence active bleeding active infection active malignancy frail with either frequent hospital admissions or unable to follow trial protocol due to differing target haemoglobin

Keywords: hemodialysis
radical versus conservative surgery in liver cystic echinococcosis: a prospective cohort study in a high-volume western centre

Conditions: Liver; Cyst, Hydatid, Granulosus (Etiology)

Summary: the goal of this observational study is to compare the results in terms of morbidity and disease-free survival between groups of patients with liver cystic echinococcosis (lce) managed with radical surgery (rs) or conservative surgery (cs), and to evaluate potential risk factors of clinically relevant biliary fistula and liver recurrence.

main hypothesis: 1. radical surgery (rs) in lce has better postoperative results than conservative surgery (cs) in terms of global morbidity, specific morbidity and liver recurrence rate. secondary hypotheses: 2. it is possible to identify preoperative and intraoperative prognostic factors of higher morbidity and recurrence rate. 3. the location of the residual pericystic layer in cs is related to a higher incidence of liver recurrence. 4. the percentage of residual pericystic layer in cs is related to a higher incidence of postoperative biliary fistula. main outcome: 1. to assess the incidence of liver recurrence between the rs and the cs groups, identifying potential risk factors. 2. to evaluate the incidence of postoperative biliary fistula between the rs and the cs groups, identifying possible risk factors. secondary outcomes: 1. to estimate the incidence of overall morbidity related to surgery. 2. to estimate the incidence of specific morbidity related to surgery (biliary fistula, intra-abdominal abscess, residual cavity abscess, hemoperitoneum, incisional infection, liver failure, respiratory infection, others). 3. to specifically analyze the incidence of postoperative biliary fistula and complex biliary fistula, and identify possible risk factors. 4. to estimate the incidence of mortality related to surgery. 5. to estimate the rate of hepatic and extrahepatic recurrence (number of disease-free months) 6. prepare a recommendation for a standardized management algorithm for lce patients based on the results obtained in the study and make it applicable to clinical practice.

Eligibility criteria:
inclusion criteria: * adult population (18 years or older) of both sexes surgically intervened for a diagnosis of lce at the bellvitge university hospital and during the period described using a conservative or radical technique. * patients with asymptomatic liver hydatid cysts of active type or transition ce1 to ce3 according to the who classification. * patients with symptomatic or complicated hepatic hydatid cysts of any type (ce1 to ce5) according to the who classification. exclusion criteria: * patients under 18 years of age. * patient operated on for lce diagnosis with inactive asymptomatic cysts (ce4 or ce5 according to the who classification). * patients with less than 1 year of follow-up.

Keywords: liver cystic echinococcosis liver hydatid hepatic resection hepatic surgery biliary fistula bile leakage recurrence risk factor
pennsylvania study of chronic obstructive pulmonary exacerbations

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the overall purpose of pa-scope is to determine why black and rural residents of pennsylvania might be at higher risk for deadly, debilitating, and costly hospitalizations for chronic obstructive pulmonary disease (copd)- and then to show that repeat acute exacerbations in high-risk patients can be reduced with one simple intervention. we believe that 1) copd patients who are black or who live in rural areas of pennsylvania are at higher risk of acute exacerbations requiring hospitalization and 2) this elevated risk can be reduced with one simple intervention: access to a 1-800 temple call center where patients can get immediate customized advice on managing copd exacerbations in their early stages. we will test these beliefs in pa-scope. the collaborators with temple university hospital on the pa-scope project are lancaster general hospital, western pennsylvania hospital, and the philadelphia college of osteopathic medicine.

* overall objective: to determine why african american and rural residents of pennsylvania might be at higher risk for deadly, debilitating, and costly hospitalizations for copd-and to show that repeat acute exacerbations in high-risk patients can be reduced with one simple intervention--access to a 1-800 temple call center phone number where patients can get immediate customized advice on managing copd exacerbations in their early stages. * phase 1: to compare and contrast the influence of race and geographic location in copd exacerbation in relation to severity, comorbidities, treatment patterns, infection rate. to identify potential risk factors for copd exacerbations leading to hospitalization. * phase 2: to reduce hospitalizations and deaths due to copd exacerbations and to improve patient quality of life, lung function, and everyday activity levels

Eligibility criteria:
inclusion criteria: * phase 1 \& gene expression: --current hospitalization for copd exacerbation * phase 1 \& 2: copd \& one of the following criteria: 1. history of hospitalization for copd exacerbation, or 2. currently on supplemental oxygen, or 3. history of evaluation for lung transplant or lvrs, or 4. \>/= 6 months post-lvrs * phase 1 or 2: 1. current or former smoker, \>/= 20 pack-yr. smoking history 2. fev1 \</= 70%; fev1/fvc \</= 70% 3. life expectancy of \> 6 months exclusion criteria: * \< 20 pack-yr. smoking history * diagnosis of pulmonary fibrosis, bronchiectasis, mediastinal mass, or presence of a pulmonary mass * asthma * fev1 \> 70% or fev1/fvc \>70%

Keywords: chronic obstructive pulmonary disease copd copd exacerbation genetic markers copd gene expression in copd exacerbations copd exacerbation symptom reporting copd exacerbation disease management copd treatment breathing disorders emphysema copd with healthy control comparators for genetic association studies.
understanding oxytocin's neural and behavioral effects in adolescents diagnosed with autism

Conditions: Autism Spectrum Disorder; Oxytocin

Summary: the investigators explored the neural and behavioral effect of oxytocin on youth with autism spectrum disorder using magnetoencephalography (meg). the investigators hypothesize that oxytocin will modulate neural activity to resemble patterns observed in the age-matched control group. thirty-two adolescents with autism and 26 typically developing adolescents participated in this randomized, double-blind meg study. individuals with autism arrived at the lab twice and received an acute dose of intranasal oxytocin or placebo in each session. during the scans, participants were asked to complete several tasks related to social perception - such as identification of social and non-social stimuli.

in the current study, the investigators aimed to explore oxytocin's influences on neural components that relate to social processing. namely, we focused on m100, m170, and m250, which tend to show atypical patterns in individuals with autism. the investigators also examined the effects of oxytocin on time dynamics - the change in specific oscillation over time and its effects on neural connectivity patterns.

Eligibility criteria:
inclusion criteria: * males, aged 12-18 years * native hebrew speakers * normal or corrected-to-normal vision * participants in the asd group had to meet the criteria for asd in the diagnostic and statistical manual of mental disorders (dsm-5) exclusion criteria: * chronic medical problems * cardiovascular risk factors * cns disease * other mental illnesses * use of prohibited medications * mental retardation * impaired vision * impaired hearing * history of significant head injury or neurological illness * current substance dependence diagnosis * metallic implants, braces or devices in the body

Keywords: autism meg social perception
function of tamsulosin in older males undergoing surgery with indwelling catheter

Conditions: Postoperative Urinary Tract Infection

Summary: this study is being done to answer the question: what is the impact of a medication called tamsulosin (also called flomax) on the rate of postoperative urinary retention (pour) and catheter-associated urinary tract infection (uti)? one of the most common complications following surgery and associated with foley catheters is post-operative urinary retention (pour) after the catheter is removed. this is defined as being unable to urinate spontaneously within 8 hours following the removal of the indwelling foley catheter (the catheter that sits in your bladder to drain urine after surgery). when this happens, it requires intermittent straight catheterization of the bladder (placing a temporary catheter in the bladder to drain the buildup of urine), which can cause a lot of discomfort and anxiety, as well as increase the risk of catheter-associated urinary tract infection (cauti).

all participants in this study will be males who are undergoing a planned surgery on their liver, gallbladder/biliary tract, pancreas, colon, or rectum for any reason. if able to obtain appropriate consent from a legal representative, cognitively impaired patients may be included. after having surgery where a catheter is placed in the bladder to drain urine (this is called a foley indwelling catheter), the catheter eventually gets removed, and some of the most frequent problems that can happen after that are post-operative urinary retention (pour) and catheter-associated urinary tract infection (cauti). the goal of this study is to see if a medicine called tamsulosin (also called flomax) can decrease the rate of pour, which means not being able to urinate spontaneously like normal, and cauti, which means an infection in the urinary tract. this study is important because pour and cauti can cause harm to patients, including discomfort if a temporary catheter has to be placed back in the bladder to get the urine out, infection, anxiety, and stress, and it's known that these complications can also increase hospital charges.

Eligibility criteria:
inclusion criteria: * planned for elective surgery for any reason (benign, malignant, or indeterminate lesion) with either an open or minimally invasive approach (hepatobiliary, pancreatic, and colorectal operations) * male and age ≥50 years * deemed physically fit for surgery exclusion criteria: * inability to obtain informed consent * age \<50 years * female * baseline creatinine \>1.5x upper limit of normal * tamsulosin therapy as a home-medication * procedure involving the prostate, bladder, ureters, or kidneys * planned foley catheter removal on the same day of surgery * planned nasogastric tube retention on postoperative day 1 * individuals taking daily phosphodiesterase 5 (pde5) inhibitors (due to the risk of symptomatic hypotension if given with tamsulosin)

Keywords: post-operative urinary retention (pour) catheter-associated urinary tract infection (cauti) flomax foley catheter
a study of stereotactic radiosurgery (srs) for people with lung cancer that has spread to the brain

Conditions: Lung Cancer; Lung Cancer Metastatic; Brain Metastases; Brain Metastases, Adult; Small-cell Lung Cancer; Small Cell Lung Carcinoma

Summary: the purpose of the study is to see if stereotactic radiosurgery/srs is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/sclc.


Eligibility criteria:
inclusion criteria: * histologic diagnosis of small cell lung cancer * radiographic diagnosis of up to 10 brain metastases on contrast-enhanced mri * age 18 and above * performance status kps 60-100/ecog 0-2 * female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment * the patient or legally authorized representative is able to provide informed consent exclusion criteria: * unable to undergo contrast-enhanced mri brain or spine * leptomeningeal disease confirmed on lumbar puncture, mri brain, or mri spine * pregnant or lactating women * prior brain-directed radiotherapy * uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on ct or pet/ct imaging, no more than 3 months before study enrollment

Keywords: stereotactic radiosurgery small cell lung cancer small cell lung carcinoma lung cancer lung cancer metastatic brain metastases 22-133 memorial sloan kettering cancer center
bridging study of c11 pittsburgh compound b (pib) and f18 flutemetamol brain positron emission tomography (pet)

Conditions: Alzheimer's Disease

Summary: the intent of this research protocol is to test the equivalency of two amyloid imaging drugs (c11 pittsburgh compound b and f18 flutemetamol). the investigators hypothesize that there will be no significant difference in the distribution of the agents to areas of amyloid deposition in the brain or to other normal brain structures. recent data have shown similarity in the distribution of the drugs in subjects with alzheimer's disease (ad) or mild cognitive impairment (mci). no comparison data of the two pet drugs in normal subjects has been published. it is important to understand differences in the images and biodistribution from the two drugs in normal subjects as nonspecific accumulation of the drugs in brain structures such as white matter appear to differ slightly and could affect image performance.

some of the current thinking in regards to the pathophysiology of ad involves the production of amyloid beta protein (ab) by secretase processing of amyloid precursor protein (app). while ab is thought to be toxic to neurons its role leading to ad pathogenesis, this is not without debate. in any case, it appears that ab forms amyloid plaques that are largely ubiquitous in ad. neuronal cell death as a result of the disease is another clear pathophysiologic finding. because of the importance of these findings in the development of ad, targeted therapies are being investigated to selectively inhibit ab production and/or manipulate amyloid load. positron emission tomography (pet) is a molecular imaging modality used to noninvasively measure functional processes of the body. a trace amount of a radiopharmaceutical is injected into a patient and the radiopharmaceutical will be taken up or localized in the body as a function of certain biological processes. the detectors of a pet scanner then measure the radiopharmaceutical distribution externally and the reconstructed pet images should represent the true distribution of the radiopharmaceutical within the body.

Eligibility criteria:
inclusion criteria: 1. males or females 30 years of age or older. 2. subjects who have the clinical diagnosis of probable ad (30) ages 50 and older who have a study partner who is the participant's power of attorney (poa) or legally authorized representative (lar), cognitive normal elderly (30) age \>60 and cognitive normal young subjects (30) ages 30-60. 3. normal subjects with clinical dementia rating (cdr) 0-0.5 and ad subjects with cdr of 0.5 or greater. exclusion criteria: 1. subjects unable to lie down without moving for 30 minutes. 2. women who are pregnant or who cannot stop breast feeding for 24 hours. 3. standard safety exclusionary criteria for mri such as metallic foreign bodies, pacemaker, etc,. 4. subjects who are too claustrophobic to perform the tests. 5. subject who have had previous brain irradiation, stroke or brain tumor(s)
nebulized versus intravenous dexmedetomidine for sevoflurane induced emergence agitation after pediatric tonsillectomy

Conditions: Emergence Agitation

Summary: pediatric patients undergoing tonsillectomy and adenoidectomy usually have a high incidence of postoperative ea, which increases the risk of developing postoperative airway obstruction and respiratory depression due to anatomical characteristics of operative location and increased susceptibility to opioid analgesics. the study will compare between nebulized and intravenous bolus of dexmedetomidine as a prophylaxis against postanesthetic emergence agitation in children undergoing tonsillectomy, adenoidectomy or adeno-tonsillectomy procedures.


Eligibility criteria:
inclusion criteria: * asa i and ii * children scheduled for tonsillectomy with or without adenoidectomy with or without myringotomy, and/or tympanostomy tube insertion. exclusion criteria: * patient's guardian refusal to participate in the study. * children with behavioral changes; physical or developmental delay; neurological disorder or psychological disorder. * children on sedative or anticonvulsant medication. * history of sleep apnea * significant organ dysfunction, cardiac dysrhythmia, congenital heart disease * known allergy to the study drugs.
kineret caps post authorisation study

Conditions: Cryopyrin-Associated Periodic Syndromes

Summary: a non-interventional, post authorization safety study to evaluate the safety of kineret in the treatment of cryopyrin associated periodic syndromes (caps) in routine clinical care with regard to serious infections, malignancies, injection site reactions, allergic reactions and medication errors, including re-use of syringe.


Eligibility criteria:
inclusion criteria: * informed consent by the patient and/or caregiver * kineret treatment will be according to the summary of product characteristics (smpc), as confirmed by the investigator exclusion criteria: * none
a study to investigate efficacy and safety of vtama® (tapinarof) cream, 1% in plaque psoriasis in the head and neck region

Conditions: Psoriasis

Summary: this is an open-label, multi-center study to evaluate the efficacy and safety of vtama (tapinarof) cream, 1% in adults with plaque psoriasis occurring in the head and neck region

this is an open-label study in which participants with plaque psoriasis in the head and neck region will be assigned to receive vtama (tapinarof) cream, 1% once daily for 12 weeks. study participants will have a follow-up period of 1 week. the study duration will be up to 17 weeks.

Eligibility criteria:
inclusion criteria: * 18 years of age or older, at the time of signing the informed consent * participants with clinical diagnosis of plaque psoriasis, including lesion(s) in the head and neck region and stable disease in the head and neck region for at least 3 months prior to the study * participant has a plaque psoriasis lesion in the head and neck region that is suitable for evaluation as the target lesion and has a pga (target lesion) score of 2 (mild), 3 (moderate), or 4 (severe) at screening and baseline * female subjects of child bearing potential who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study * negative pregnancy test at baseline (day 1) * capable of giving written informed consent exclusion criteria: * diagnosis of a type of psoriasis other than plaque psoriasis * any sign of infection of any of the psoriatic lesions * concurrent significant dermatologic or inflammatory condition other than plaque psoriasis that, in the investigator's opinion, would make it difficult to interpret data or assessments during the study * history of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, may interfere with participation in the study and ability to understand and give informed consent * history of sensitivity to the study product, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study * previous known participation in a clinical study with tapinarof (previously known as gsk2894512 and wbi-1001); previous or current use of vtama® (tapinarof) cream, 1% * use of any prohibited medication or procedure within the indicated period before the baseline visit including other investigational product within 30 days or 5 half-lives of the investigational product (whichever is longer) * uv light therapy or prolonged exposure to natural or artificial sources of uv radiation (e.g., phototherapy, tanning beds/booths, or therapeutic sunbathing) within 4 weeks prior to the baseline

Keywords: tapinarof plaque psoriasis scalp psoriasis psoriasis phase 4 topical open-label efficacy safety adult face psoriasis neck psoriasis psoriatic conditions
family intervention following traumatic injury

Conditions: Acquired Brain Injury; Spinal Cord Injuries

Summary: the purpose of this study is to investigate the effectiveness of a manualized intervention (fits) to families living with brain injury or spinal cord injury. the intervention will be provided by a trained neuropsychologist and consists of 8 structured sessions of 90 minutes duration. the intervention group will be compared to a control group receiving treatment as usual, one psycho-educational group session of a 2 hour duration.


Eligibility criteria:
inclusion criteria: * acquired brain injury or spinal cord injury * talk and read danish * minimum 6 months to 2 years since discharge * family members must be actively involved in the patient's rehabilitation exclusion criteria: * severe aphasia * families, where other family members require a substantial amount of care * prior psychiatric or neurological disease